EP0759976A1 - Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages - Google Patents

Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Info

Publication number
EP0759976A1
EP0759976A1 EP94919078A EP94919078A EP0759976A1 EP 0759976 A1 EP0759976 A1 EP 0759976A1 EP 94919078 A EP94919078 A EP 94919078A EP 94919078 A EP94919078 A EP 94919078A EP 0759976 A1 EP0759976 A1 EP 0759976A1
Authority
EP
European Patent Office
Prior art keywords
phage
antibody
antibodies
catalytic
sep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94919078A
Other languages
German (de)
English (en)
Other versions
EP0759976A4 (fr
Inventor
Rodger G. Smith
John Mccafferty
David Chiswell
Michael J. Darsley
Kevin Fitzgerald
John H. Kenten
Mark T. Martin
Richard C. Titmas
Richard O. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGEN International Inc
Original Assignee
IGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGEN Inc filed Critical IGEN Inc
Publication of EP0759976A1 publication Critical patent/EP0759976A1/fr
Publication of EP0759976A4 publication Critical patent/EP0759976A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

On décrit et on revendique des procédés pour produire des anticorps catalytiques, en particulier des anticoprs catalytiques humains, à partir de bactériophages. Les procédés consistent à cloner, sélectionner, trier et isoler les anticorps catalytiques. Egalement, on décrit et on revendique les produits eux-mêmes, les anticorps catalytiques, préparés par cette technolgie faisant appel à des phages. En plus, on décrit et on revendique les anticorps catalytiques produits par la technologie faisant appel à des phages et qui sont utiles pour l'activation de précurseurs de médicaments. Finalement, l'invention concerne également la production d'anticorps à action catalytique vis-à-vis des phosphonates.
EP94919078A 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages Withdrawn EP0759976A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/003420 WO1995027045A1 (fr) 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Publications (2)

Publication Number Publication Date
EP0759976A1 true EP0759976A1 (fr) 1997-03-05
EP0759976A4 EP0759976A4 (fr) 2001-02-07

Family

ID=22242396

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94919078A Withdrawn EP0759976A4 (fr) 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Country Status (4)

Country Link
EP (1) EP0759976A4 (fr)
JP (1) JPH10507341A (fr)
AU (1) AU695406B2 (fr)
WO (1) WO1995027045A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
CA2334170A1 (fr) 1998-07-27 2000-02-10 Genentech, Inc. Efficacite de transformation amelioree de l'expression a la surface des phages par modification d'une proteine de coque
ES2564161T3 (es) * 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
DE60224720D1 (en) 2001-11-22 2008-03-06 Univ Keio Re
WO2003104418A2 (fr) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Polypeptides reconstitues
FI20022048A0 (fi) 2002-11-18 2002-11-18 Valtion Teknillinen Ei-kompetetiivinen immunomääritys pienille analyyteille
WO2021167952A2 (fr) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Anticorps agonistes dirigés contre l'endogline (eng) et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (fr) * 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
AU668374B2 (en) * 1991-12-10 1996-05-02 Dana-Farber Cancer Institute Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof

Also Published As

Publication number Publication date
AU7014194A (en) 1995-10-23
WO1995027045A1 (fr) 1995-10-12
AU695406B2 (en) 1998-08-13
JPH10507341A (ja) 1998-07-21
EP0759976A4 (fr) 2001-02-07

Similar Documents

Publication Publication Date Title
US5855885A (en) Isolation and production of catalytic antibodies using phage technology
JP4414900B2 (ja) Ｌ鎖欠落免疫グロブリン
JP3176917B2 (ja) 特異的結合対の構成員を製造する方法
US6096551A (en) Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1709081B1 (fr) Polypeptides hybrides capables d'activer des recepteurs
EP1550729B1 (fr) Polypeptides se fixant à une cible comprenant un domaine de type immunoglobuline (IG-like) VL fusioné à une domaine de type immunoglobuline (IG-like) VH
EP0580737B1 (fr) Banques de recepteurs heterodimeres utilisant des phagemides
EP0894135B1 (fr) Proteine, polyvalente et a specificites multiples, de fixation sur un antigene
JP3507073B2 (ja) 特異的結合対の成員の製造方法
Yazaki et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
EP0425661B1 (fr) Nouveau procede d'exploitation du repertoire immunologique
EP0732404A1 (fr) Nouveau vecteur de detection d'expression
US7067284B1 (en) Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH06121696A (ja) 抗原結合性タンパク質およびその製造方法
WO1999025818A1 (fr) Procede pour identifier des domaines de sites de fixation qui preservent leur capacite de fixation sur un epitope
US20050207977A1 (en) Multimeric protein engineering
Dziegiel et al. Phage display used for gene cloning of human recombinant antibody against the erythrocyte surface antigen, rhesus D
Kivi et al. HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
WO1995027045A1 (fr) Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages
Kim et al. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies
CN112521497B (zh) 肌红蛋白单克隆抗体的制备和应用
ITRM930818A1 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati anticorpi prodotti e loro uso in diagnosi e terapia.
JP2004283175A (ja) ファージ技術を用いる触媒性抗体の単離および産生
Billiald et al. Production of a functional anti-scorpion hemocyanin scFv in Escherichia coli
CA2186469A1 (fr) Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IGEN INTERNATIONAL, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 9/00 A, 7C 07K 16/00 B, 7A 61K 38/43 B

A4 Supplementary search report drawn up and despatched

Effective date: 20001222

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011024

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/00 B

Ipc: 7C 12N 9/00 A

RTI1 Title (correction)

Free format text: THE ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODIES USING PHAGE TECHNOLOGY

RTI1 Title (correction)

Free format text: ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODIES USING TWO AFFINITY PEPTIDES IN TANDEM

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060308